...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development
【24h】

Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development

机译:建立基于证据的非临床路线图,以评估新结核病(TB)药物方案的功效:结核病药物方案的关键途径-过敏和感染性疾病国家研究所在体内TB药物开发的体内药理学研讨会

获取原文
获取原文并翻译 | 示例
           

摘要

Novel tuberculosis (TB) drug regimens are urgently needed, and their development will be enabled by improved preclinical approaches that more effectively inform and ensure safe selection of clinical candidates and drug combination/regimens. An evidence-based approach for the assessment of nonclinical models supporting TB drug development has been proposed by a joint partnership between the National Institute of Allergy and Infectious Diseases (NIAID) and the Critical Path to TB Drug Regimens (CPTR) Consortium.
机译:迫切需要新的结核病(TB)药物治疗方案,其发展将通过改进的临床前方法来实现,这些方法可以更有效地告知并确保安全选择临床候选药物和药物组合/方案。国家过敏和传染病研究所(NIAID)与结核病药物治疗关键途径(CPTR)联盟之间的联合伙伴关系提出了一种基于证据的方法来评估支持结核病药物开发的非临床模型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号